Birgitta Grundmark (MD, PhD) is a pharmacoepidemiologist and senior pharmacovigilance expert. Her research focus is methodology development for global monitoring of adverse drug reactions, and since the onset of the COVID-9 pandemic she is specialising on safety issues related to the treatments for COVID-19. Grundmark is also an experienced drug regulator and an independent expert member of the EU Pharmacovigilance Risk Assessment Committee (PRAC).